Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes
Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes
复制标题
DOI：
10.1016/s0002-9149(02)02569-9
复制
发表时间：
2002-09-15
影响因子：
2.8
通讯作者：
Cannon, CP
中科院分区：
文献类型：
--
作者：
Brener, SJ;Murphy, SA;Cannon, CP
在TACTICS-TIMI 18试验中，在137例接受介入治疗的单支血管疾病患者、224例接受罪犯血管介入治疗的多支血管疾病患者和66例接受多支血管介入治疗的多支血管疾病患者中，6个月时死亡、心肌梗死或因不稳定型心绞痛再次住院的发生率分别为17.5%、23.2%和21.2%，（p = 0.44）。在接受多支血管介入治疗的患者中，后续非罪犯血管介入治疗较低（分别为1.5%、6.3%和1.5%; p = 0.04）。因此，多支血管介入治疗在患有急性冠状动脉综合征的多支血管疾病患者中安全有效。
In the TACTICS-TIMI 18 trial, in 137 patients with single-vessel disease who underwent intervention, 224 patients with multivessel disease who underwent culprit vessel intervention, and 66 patients with multivessel disease who underwent multivessel intervention, the incidence of death, myocardial infarction, or rehospitalization for unstable angina at 6 months was 17.5%, 23.2%, and 21.2%, respectively (p = 0.44). Subsequent nonculprit vessel intervention was lower in the patients who underwent multivessel intervention (1.5%, 6.3%, and 1.5%, respectively; p = 0.04). Thus, multivessel intervention is safe and effective in patients with multivessel disease who have acute coronary syndromes.